fbpx

PSA partner in PRIDE project, supporting safe and inclusive care for LGBTQIA+ Australians

28 June 2024

 

The Pharmaceutical Society of Australia (PSA) is proudly partnering with the University of Queensland (UQ) to foster inclusive and empowered primary care workforces through the Promoting queer-inclusive professional identities for diversity in primary healthcare (PRIDE co-design) project.

 

Funded through the Medical Research Future Fund (MRFF), the PRIDE project aims to make affirming care more accessible through a national network of empowered LGBTQIA+ practitioners and allies, building capacity of the mainstream primary care sector to address the health needs of the LGBTQIA+ community in a safe and inclusive way.

 

The project will work with a range of peak professional bodies to deliver tailored education to health professionals. As a PRIDE project partner, PSA will offer education and resources to help pharmacists improve the care they provide LGBTQIA+ patients, starting with a session at PSA’s national conference in August.

 

PSA National President Associate Professor Fei Sim FPS said there is still a long way to go to addressing health inequalities for LGBTQIA+ Australians.

 

“Everyone has the right to safe, affirming health care,” Associate Professor Sim said.

 

57% of LGBTQIA+ Australians have reported discrimination due to their sexual orientation, and almost 80% of people who are trans or gender diverse had experienced discrimination due to their gender identity. Stigma and discrimination in the health care context contributes to greater health disparities experienced by LGBTQIA+ communities and can lead to delaying or avoiding healthcare entirely.

 

“As some of the most accessible health care professionals, pharmacists have a duty of care to patients to ensure that healthcare is provided in a way that is inclusive and appropriate for all people.

 

“PSA strongly believes in the potential of PRIDE co-design project to have a transformative impact on the development of inclusive and affirming models of care for LGBTQIA+ people experiencing intersectional disadvantage within our health care system.

 

“We are proud to be working with Dr Ross and her team to provide pharmacists with the resources and training needed to promote truly person-centred care,” A/Prof Sim concluded.

 

PRIDE Project leader and Chief Investigator Dr Megan Ross highlighted the importance of creating a culture of safe and supportive environments for LGBTQIA+ health practitioners, too.

 

“Building the capacity of the primary health workforce to deliver safe and affirming care has to include creating safe and inclusive environments for health providers. Too often we see trans and queer practitioners exit the workforce, we need a culture of inclusion that supports LGBTQIA+ practitioners to remain in the workforce and provide safe and affirming care to the community,” Dr Ross said.

 

“Building multi-disciplinary, connected and trusted network of safe and affirming providers addresses a current gap in primary care.

“A multi-disciplinary affirming provider network will facilitate access to continuous, trustable safe and affirming care across the primary care landscape for LGBTQIA+ consumers, and support LGBTQIA+ practitioners to feel safe and supported in their workplaces.”

 

Delegates attending PSA24 will have the opportunity to connect with the PRIDE Project during the session Does the pharmacy profession get a rainbow tick? presented by Professor Lisa Nissen and Dr Jean Spinks on Sunday 4 August, 2024.

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Media statement: Vaping reform legislation

26 June 2024

 

The Pharmaceutical Society of Australia (PSA) acknowledges the passing of reforms today that aim to shut down the retail model of vape supply in Australia.

 

The legislation which has now passed the Senate defines the minimum legal requirements for prescribing as a Pharmacist Only Medicine (Schedule 3). In addition, pharmacists will be expected to adhere to PSA’s Guidelines for pharmacists providing smoking cessation support, which will be updated prior to 1 October 2024.

 

While the amendments to the legislation are not PSA’s preferred approach, we also recognise the need for strong action to address the vaping public health crisis, and this starts with ending retail supply of vapes.

 

Quotes attributable to PSA National President Associate Professor Fei Sim:


“PSA has consistently called for strong action to address the public health crisis that vaping has become.

 

“While this is not our preferred model, PSA remains firm in the belief that something needed to be done to prevent another generation of Australians to becoming addicted to nicotine and experiencing the health consequences of vaping.

 

“Once legislation has passed both houses, our focus will be firmly on supporting pharmacists through these changes.

 

“PSA will work with government to support the pharmacists who choose to be involved in the prescribing and dispensing of nicotine-containing therapeutic vapes. PSA will develop best-practice guidelines to describe how pharmacists prescribe products for smoking cessation products, including nicotine-containing therapeutic vapes.

 

“People will not be able to simply buy vapes on request – they must take part in a therapeutic consultation with a pharmacist who will prescribe a therapy based on clinical need.  It will be very different to how Australians are currently buying vapes.

 

“The coming months will be critical in ensuring pharmacists and the community have a clear understanding of how this model will work as a health-based approach to nicotine dependence management.”​

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

PSA position on proposed vaping reforms

25 June 2024

 

Based on current information, the Pharmaceutical Society of Australia (PSA) is not supportive of proposed amendments to the Therapeutic Goods and other Legislation (Vaping Reforms) Bill 2024 which are before Parliament this week.

If the proposed amendment to downschedule nicotine vaping products becomes part of the final legislation, there would not be an adequate transition of nicotine-vaping being a retail product to it becoming a health-care professional prescribed tool to support smoking cessation.

Quotes attributable to PSA National President Associate Professor Fei Sim:

“Vaping is a public health crisis; It has unique harms which are different from tobacco smoking, and we share the government’s concerns that another generation is becoming dependent on nicotine.

“Doing nothing is not an option – and therefore, we continue to support the government’s intent as outlined in the original vaping reform legislation.

“Further, PSA continues to strongly support the government’s intent to limit the supply of vaping and removing vapes from retail settings.

“However, the amendment proposed undermines the role of pharmacists as health care professionals.

“The amendment – if it was to pass the Senate in its current form – asks pharmacists to prescribe unapproved, unregulated, untested vaping products to the public.

“This would not represent a health model. Pharmacist Only Medicines are pharmacist-prescribed medicines, which include a consultation with patients to establish therapeutic need. Not having patient information recorded in the prescribing of nicotine-containing vapes is inconsistent with the normal provision of health care.

“We cannot and do not support positioning pharmacists as retailers rather than health professionals.

“Pharmacists can and should be involved in harm minimisation and nicotine dependence management, but in the absence of a TGA-approved product, effective clinical governance framework and evidence-based clinical guidelines supporting their use, we cannot embed a therapeutic model of prescribing vapes.

“PSA’s role is to support pharmacists to practise and perform their clinical tasks professionally and ethically. PSA will, in good faith, continue to have constructive discussions with stakeholders on this important public health issue.

“PSA maintains support for the original intent of the Bill, to limit the supply of therapeutic vapes through prescription only and taking them out of the hands of children.”

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

PSA Faye McMillan Conference Grant recipients announced

24 June 2024

 

 

The Pharmaceutical Society of Australia (PSA) is proud to announce the recipients of the second annual PSA Faye McMillan Conference Grant.

This grant provides a unique opportunity for recipients to attend the PSA National Conference in Sydney from 2-4 August, supporting the continued professional development of First Nations pharmacists.

 

Inspired and supported by Professor McMillan herself, the PSA Faye McMillan Conference Grant is awarded each year to Aboriginal and/or Torres Strait Islander pharmacists to attend Australia’s leading pharmacist education conference hosted by PSA.

 

Thanks to the generosity of this year’s grant sponsors Care Pharmaceuticals and Hydralyte, and AstraZeneca, PSA is proudly supporting three pharmacists to attend PSA24.

The recipients of the PSA Faye McMillan Conference Grant for 2024 are:

  • Timothy Hockam
  • Elizabeth Dening
  • Kirralee Natty

 

Quotes attributable to Professor Faye McMillan AM FPS:

“Congratulations to all the recipients. Belonging is such a critical aspect of being part of a profession, and the relationship with PSA provides a sense of belonging. I hope all the recipients enjoy every aspect of PSA24, and I look forward to seeing them there.”

Quotes attributable to PSA National President Associate Professor Fei Sim FPS:

 

“As we celebrate the recipients of the PSA Faye McMillan Conference Grant, PSA reaffirms our commitment to nurturing diversity and inclusion within the pharmacy profession.

 

“Supporting First Nations pharmacists is not just about equity; it’s about recognising and harnessing the unique perspectives and contributions they bring to the healthcare landscape.

“Congratulations to Timothy, Elizabeth and Kirralee, we are excited to have you as part of this year’s conference.”

Quotes attributable to Marketing Manager of Care Pharmaceuticals and Hydralyte Joan Isaac:

“We are proud sponsors of the PSA Faye McMillan Grant, recognising the remarkable achievements of Indigenous pharmacists like Professor Faye McMillan in advancing healthcare equity. By supporting this initiative, Care Pharmaceuticals and Hydralyte affirm our dedication to fostering inclusivity and diversity within the pharmacy profession, ensuring culturally sensitive care for all.

 

“As leading providers of innovative healthcare solutions for Australian families, Care Pharmaceuticals and Hydralyte are honoured to sponsor the PSA Faye McMillan Grant. This sponsorship reflects our commitment to empowering Aboriginal and Torres Strait Islander pharmacists to attend the PSA National Conference, contributing to discussions on improving Indigenous healthcare and building a more representative pharmacy workforce for the benefit of all Australians.”

Quotes attributable to Country President of AstraZeneca Australia and New Zealand Ben McDonald:

“Pharmacists are critical to providing front line health care to communities across Australia. Increasing the representation of pharmacists who identify as Aboriginal or Torres Strait Islander is crucial in supporting and delivering culturally appropriate health care.

“AstraZeneca is proud to support the ongoing professional development of First Nations pharmacists by partnering with the PSA’s Faye McMillan Conference Grant.”

 

PSA24 is a premier platform for pharmacists to exchange knowledge, foster collaborations, and explore innovations shaping the future of healthcare. With the support of the PSA Faye McMillan Conference Grant, these exceptional pharmacists will have the opportunity to engage with peers, expand their skill sets, and contribute to advancing pharmacy practice in Australia.

About Professor Faye McMillan AM

Professor Faye McMillan AM is a Wiradjuri yinaa (woman) originally from Trangie, NSW. She is a dedicated community pharmacist and is recognised as the first Indigenous Australian to hold a western degree in pharmacy in this country.

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

PSA, PDL partner to launch conference volunteer award

21 June 2024

The Pharmaceutical Society of Australia (PSA) and Pharmaceutical Defence Limited (PDL) have joined forces to deliver National Conference Volunteer Program, giving pharmacy students from universities around the country the chance to connect with their peers and experience one of Australia’s leading pharmacy conferences.

 

As part of the program one outstanding student volunteer will receive the PDL PSA Conference Volunteer of the Year award, and a $500 contribution toward further education.

 

National President Associate Professor Fei Sim FPS launched PSA’s partnership with PDL, welcoming the opportunity to thank and celebrate PSA24’s student volunteers.

 

“Our student volunteers make a huge difference to our conferences,” A/Prof Sim said.

 

“We are proud to not only provide students with the opportunity to experience the conference, but also to offer a tailored volunteer program including an interactive education session with PDL as part of their experience.

 

“We are thrilled to also be able to join PDL to recognise the hard work and dedication of PSA24’s student volunteers. On behalf of PSA I express our gratitude to PDL for their ongoing support of the pharmacy profession, including the future pharmacists who volunteer with us at PSA24.

 

PDL Chair Paul Naismith MPS looks forward to PSA24 and supporting the student volunteers.

 

“We are delighted to partner with PSA for their national conference volunteer program. Student volunteers play a key role in running pharmacy conferences, and we look forward to awarding an outstanding volunteer at PSA24.

 

“PDL is pleased to support initiatives that help students get involved in the profession.”

 

Attendees will be able to nominate student volunteers throughout the conference, with the award presented at Sunday’s closing plenary.

 

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

NSW pharmacists to treat skin conditions in trial expansion

17 June 2024

 

 

Pharmacists in New South Wales will soon be able to supply treatment for four skin conditions under the next phase of the NSW Pharmacy Trial.

Participating NSW pharmacists who undertake additional training will be able to treat impetigo, shingles, atopic dermatitis, and mild plaque psoriasis under the trial.

Pharmaceutical Society of Australia (PSA) New South Wales President Luke Kelly FPS welcomed the next phase of the NSW Pharmacy Trial, and reaffirmed PSA’s support for pharmacists participating in the program.

“Under the next phase of the New South Wales Pharmacy Trial community pharmacists will be trained to treat four skin conditions, making treatment for conditions including impetigo, shingles, eczema, and mild plaque psoriasis more accessible around our state,” Mr Kelly said.

“Pharmacists are key to strengthening the healthcare system, and through the NSW Pharmacy Trial, patients have been able to access safe, quality treatment when and where they need it.

“For skin conditions like shingles, acute eczema, mild plaque psoriasis and impetigo, providing timely, accessible treatment is critical to relieving discomfort and pain, and allow us to mitigate further complications.

“New South Wales pharmacists have already supported thousands of patients with a range of health concerns, including uncomplicated Urinary Tract Infections and extending the supply of the oral contraceptive pill. With the inclusion of skin conditions, pharmacists can continue to provide nation-leading, accessible care to patients across the state.

Mr Kelly also welcomed increased remuneration for pharmacists providing consultations skin conditions, better reflecting clinical expertise and administration costs.

“Increased support for pharmacists means we can ensure services remain available to patients across our state, at no cost.

“We look forward to continuing to work closely with Minister Park, the New South Wales Government and other stakeholders to ensure we are best responding to the health needs of our communities,” Mr Kelly said.

New South Wales pharmacists can now enrol in and complete prerequisite training here.

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Queensland Budget sets pharmacists up for Scope of Practice Pilot

11 June 2024

 

The Pharmaceutical Society of Australia (PSA) welcomes education funding for pharmacists in the Miles Government’s 2024-25 Queensland State Budget.

 

Today’s state budget commits $6 million to enable pharmacists to complete additional training to support the state-wide rollout of the Queensland Community Pharmacy Scope of Practice Pilot. This includes completion of prescribing training and clinical practice training, and will allow participating pharmacists to treat and prescribe medicines for common health conditions and wellbeing services, making healthcare more accessible for Queenslanders.

 

PSA also welcomes the government’s $72.9 million investment in free vaccinations for Queenslanders, including $40 million to fund influenza vaccines for all Queenslanders aged over 6 months, $26 million to fund meningococcal B vaccines for eligible infants, children, and adolescents, and $6.9 million to fund RSV vaccines.

 

PSA Queensland President Mr Shane MacDonald said the budget gives pharmacists the support they need to prepare for Australia’s most progressive scope of practice pilot.

 

“Investment in pharmacists ensures that our workforce is ready to offer expanded health services to Queenslanders,” Mr MacDonald said.

 

“Financial support to help meet training costs means more pharmacists participating in the pilot, and more services in more communities.

 

“We thank the Miles Government for their continued support and collaboration with the profession to bring the Scope of Practice Pilot to Queenslanders, better utilising the skills and accessibility of pharmacists to improve access to healthcare across the state.

 

“PSA is pleased to again welcome the continuation of free influenza vaccines for Queenslanders in 2025, easing the cost burden of essential vaccines on Queensland families,” Mr MacDonald continued.

 

“Knowing that every patient will have access to a vaccination at no cost, pharmacists can proactively plan now for the 2025 flu season.”

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Pharmacists named in King’s Birthday Honours

11 June 2024

 

The Pharmaceutical Society of Australia (PSA) has recognised and congratulated the PSA members and pharmacists named on the 2024 King’s Birthday Honours List.

PSA Life Member Robert Dean MPS of Red Cliffs in Victoria was recognised for his service to the community of Red Cliffs, including fifty years as a community pharmacist.

Farag Gobran MPS of Drummoyne in New South Wales was recognised for his service to youth, to aged welfare, and to the Egyptian community, as well as his service as a community pharmacist since 1970.

PSA also acknowledges Former Department of Health and Aged Care Deputy Secretary, Health Products Regulation Group Professor John Skerritt, recognised as a Member of the Order of Australia in the General Division.

PSA National President Associate Professor Fei Sim FPS congratulated the recipients.

“We know that pharmacists make enormous contributions to our communities, through the care we provide but also as pillars of community life,” Associate Professor Sim said.

“Robert and Farag are two pharmacists who’ve supported their communities not only through their careers as pharmacists, but also through lifetimes of service to their communities.

“On behalf of PSA and Australian pharmacists, we congratulate Mr Dean, Mr Gobran and Professor Skerritt on their achievements and continued commitment to the health of our communities.”

 

 

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Health Minister to address PSA national conference

6 June 2024

 

Minister for Health and Aged Care, the Hon. Mark Butler MP will again join pharmacists at the Pharmaceutical Society of Australia’s National Conference PSA24, providing the ministerial address on behalf of the Albanese Government.

In what is a critical time for the pharmacy profession, the presence of Minister Butler underscores the important role of pharmacists in meeting the changing healthcare needs of Australians.

PSA24’s ‘Pathways to Progress’ will give pharmacists the opportunity to engage with industry leaders, policymakers, and colleagues from all corners of the country. With more than 40 education sessions and opportunities to hear from both the government and opposition, PSA24 is set to be the biggest national conference yet.

PSA National President Associate Professor Fei Sim FPS said that the Minister’s address at the conference will provide further insights into PSA’s Strategic Agreement on Pharmacist Professional Practice announced earlier this week.

“At this critical juncture for the pharmacy profession, the Minister’s presence recognises the irreplaceable role pharmacists play in quality and safe use of medicines, and in contributing to improved Australians’ access to healthcare,” Associate Professor Sim said.

“The signing of the 8th Community Pharmacy Agreement and the PSA Strategic Agreement this week are a clear indication of the federal government’s belief in pharmacists and our fundamental role in Australia’s health system.

“This is an important opportunity for our profession to hear directly from the Minister about the government’s policy agenda and priorities for the next 12 months and beyond. We are thrilled to again welcome the Minister to PSA24 in Sydney this August.

“I call on all pharmacists and pharmacy students to attend the PSA24 Conference in Sydney as we continue our advocacy to expand pharmacists’ roles, recognition and remuneration.

The Assistant Minister for Mental Health and Suicide Prevention and Assistant Minister Rural and Regional Health, the Hon. Emma McBride MP, and Shadow Minister for Health and Aged Care, Senator the Hon Anne Ruston are also set to appear at PSA24.

PSA24 will be held at the new bigger venue of the International Convention and Exhibition Centre from Friday 2 August to Sunday 4 August 2024.

Registration for the PSA national conference is now open. For more information and to secure your spot, visit www.psa24.com.au

PSA welcomes 8th Community Pharmacy Agreement, and enters into Strategic Agreement on Pharmacist Professional Practice

3 June 2024

 

 

The Pharmaceutical Society of Australia (PSA) welcomes the announcement today that the Australian Government and Pharmacy Guild of Australia has finalised the 8th Community Pharmacy Agreement. PSA welcomes the certainty the 8CPA brings to the community pharmacy sector, and confidence it brings to the viability of Australia’s community pharmacies.

 

For the last 12 months, the community pharmacy sector has had uncertainty. The 8CPA delivers funding boost of $3billion for community pharmacy activities, certainty of funding for dose administration aids, staged supply, MedsChecks and the Regional Pharmacy Maintenance Allowance.

 

PSA has also announced the signing of the Strategic Agreement on Pharmacist Professional Practice was signed in Canberra today by National President A/Prof Fei Sim and the Minister for Health and Aged Care the Hon. Mark Butler.

 

The key Strategic Agreement with the Australian Government contains a program of work to deliver contemporary fundamental standards and guidelines that define pharmacy practice across all areas of practice.

 

Together, both agreements secure the most significant federal government commitment to supporting professional pharmacy practice in history, lifting the bar in quality of care and breadth of services delivered by pharmacists across the health system.

 

Discussions will continue for programs not contained in the 8CPA, including those delivered by pharmacists in all other areas of practice. PSA looks forward to leading further engagement with government in relation to these programs during the remainder of 2024.

 

Quotes attributable to PSA National President Associate Professor Fei Sim:

 

“On behalf of our members, PSA welcomes the signing of the 8th Community Pharmacy Agreement for the certainty it provides the sector. The funding committed by the Albanese government in the 8CPA is positive for community pharmacies and will result in more accessible care for patients through a strong, thriving and viable community pharmacy network.

 

“In particular, I thank Minister for Health and Aged Care Mark Butler for his commitment, alongside PSA, to continue advancing the profession through a key Strategic Agreement on pharmacy practice.

 

“PSA’s intent through its negotiations with government is to ensure pharmacists are supported to do what they do best – support the health and wellbeing of Australians through providing access to health care and making the use of medicines safer.

 

“PSA’s Strategic Agreement on Pharmacist Professional Practice acknowledges that the role of pharmacists is changing and evolving, and with that comes the need to further develop the fundamental guidelines that underpin all elements and areas of pharmacy practice. This will ensure pharmacists can continue to deliver high standards and quality services which Australians rely on in a sustainable manner.

“While today is a milestone in negotiations regarding community pharmacy-delivered programs and services with government, there is more to be done.

“We are focused in continuing our work with Minister Butler and the Department of Health and Aged Care which will define the design, implementation and evaluation of pharmacist-led programs which are not in the 8CPA.

“We continue our commitment on supporting the pharmacy workforce through practice support and education which has always been one of the core responsibilities of the PSA.”

Quotes attributable to PSA Lead Negotiator Dr Shane Jackson:

 

“The 8PCA is a positive outcome for the profession and the Australian community. It will help improve access to care in a sustainable manner.

“PSA’s strategic agreement focuses on supporting pharmacists, and helping pharmacists demonstrate the value of what we do. It provides a pathway to create data and evidence to demonstrate the need for long-term, continued funding for programs we know are critical to the Quality Use of Medicines.

“Now that the 8CPA and Strategic Agreement on Pharmacist Professional Practice have been announced, we turn our focus to providing a structure for optimisation of programs no longer contained in the 8CPA, as well as new programs that may be delivered by pharmacists.”

 

 

A copy of the PSA Strategic Agreement on Pharmacist Professional Practice is available on the Department of Health website.

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au